CIK 0001404644
- Non-accelerated filer
- Smaller reporting company
Neurogene Inc.
Sign in to watch- Ticker
- NGNE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 980542593
- Phone
- +1 877-237-5020
- Business address
- 535 W 24TH STREET, 5TH FLOOR, NEW YORK, NY, 10011
- Former names
- Neoleukin Therapeutics, Inc., AQUINOX PHARMACEUTICALS, INC, AQUINOX PHARMACEUTICALS (USA) INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2017-03-08 | Mitchell David Chilton VP Global Regulatory & Quality | Grant or award · Stock Option (Right to Buy) | +25,000 | 25,000 | ||
| 2016-03-10 | Mitchell David Chilton VP Global Regulatory & Quality | Grant or award · Stock Option (Right to Buy) | +25,000 | 25,000 | ||
| 2015-08-24 | Mitchell David Chilton VP Global Regulatory & Quality | Purchase | +3,575 | $17.81 | $64K | 3,575 |
| 2015-08-11 | Mitchell David Chilton VP Global Regulatory & Quality | Purchase | +1,600 | $24.36 | $39K | 1,600 |
| 2015-01-11 | Mitchell David Chilton VP Global Regulatory & Quality | Grant or award · Stock Option (Right to Buy) | +35,000 | 35,000 |
Page 1 of 1 · 5 trades